Cargando…

Efficacy and safety of insulin glargine 300 U/mL vs insulin degludec in patients with type 2 diabetes: A randomized, open‐label, cross‐over study using continuous glucose monitoring profiles

AIMS/INTRODUCTION: Compared with glargine 100 U/mL (Gla100), glargine 300 U/mL (Gla300) and degludec (Deg) – the ultralong‐acting insulins – reportedly have more stable effects and reduce the risk of hypoglycemia. Currently, they are considered to be the most useful basal insulins. The present study...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kawaguchi, Yuji, Sawa, Jun, Sakuma, Noriko, Kumeda, Yasuro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6400202/ https://www.ncbi.nlm.nih.gov/pubmed/29947060 http://dx.doi.org/10.1111/jdi.12884

Ejemplares similares

Differential Effect of Hypoalbuminemia on Hypoglycemia on Type 2 Diabetes Patients Treated with Insulin Glargine 300 U/ml and Insulin Degludec
por: Kawaguchi, Yuji, et al.
Publicado: (2019)

Comparison of the efficacy and safety of insulin degludec/aspart (twice‐daily injections), insulin glargine 300 U/mL, and insulin glulisine (basal–bolus therapy)
por: Kawaguchi, Yuji, et al.
Publicado: (2019)

Insulin degludec and insulin glargine 300 U/mL: Which of these two insulins causes less hypoglycemia?
por: Buscemi, Silvio, et al.
Publicado: (2019)

Response to insulin degludec and insulin glargine 300 U/mL: Which of these two insulins causes less hypoglycemia?
por: Yamabe, Mizuho
Publicado: (2019)

Day‐to‐day variability of porcine lente, insulin glargine 300 U/mL and insulin degludec in diabetic dogs
por: Miller, Michelle, et al.
Publicado: (2021)

In Silico Head-to-Head Comparison of Insulin Glargine 300 U/mL and Insulin Degludec 100 U/mL in Type 1 Diabetes
por: Schiavon, Michele, et al.
Publicado: (2020)

Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL and insulin degludec 100 U/mL in older participants in the BRIGHT trial
por: Bolli, Geremia B., et al.
Publicado: (2021)

Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml
por: Steinstraesser, A, et al.
Publicado: (2014)

A comparative effectiveness study of degludec and insulin glargine 300 U/mL in insulin‐naïve patients with type 2 diabetes
por: Tibaldi, Joseph, et al.
Publicado: (2019)

Comparison of insulin glargine 300 U/mL and insulin degludec using flash glucose monitoring: A randomized cross‐over study
por: Yamabe, Mizuho, et al.
Publicado: (2018)

Comment on “a comparative effectiveness study of degludec and insulin glargine 300 U/mL in insulin‐naïve patients with type 2 diabetes”
por: Freemantle, Nick, et al.
Publicado: (2019)

Insulin degludec: Lower day‐to‐day and within‐day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes
por: Heise, Tim, et al.
Publicado: (2017)

Comparative Effectiveness of Switching From First-Generation Basal Insulin to Glargine 300 U/ml or Degludec 100 U/ml in Type 1 Diabetes: The RESTORE-1 Study
por: Laviola, Luigi, et al.
Publicado: (2020)

Insulin depot absorption modeling and pharmacokinetic simulation with insulin glargine 300 U/mL
por: Lindauer, Klaus, et al.
Publicado: (2019)

Nocturnal Glycemic Control with New Insulin Glargine 300 U/mL
por: Yu, Neng Chun
Publicado: (2019)

Effectiveness and Safety of Insulin Glargine 300 U/ml in Comparison with Insulin Degludec 100 U/ml Evaluated with Continuous Glucose Monitoring in Adults with Type 1 Diabetes and Suboptimal Glycemic Control in Routine Clinical Practice: The OneCARE Study
por: Conget, Ignacio, et al.
Publicado: (2021)

Low Blood Glucose Index and Hypoglycaemia Risk: Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in Type 2 Diabetes
por: Kovatchev, Boris, et al.
Publicado: (2020)

Comparison of morning basal + 1 bolus insulin therapy (insulin glulisine + insulin glargine 300 U/mL vs insulin lispro + insulin glargine biosimilar) using continuous glucose monitoring: A randomized crossover study
por: Takeishi, Soichi, et al.
Publicado: (2017)

Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U300 in the Netherlands: Evidence From a Randomised Controlled Trial
por: Evans, Marc, et al.
Publicado: (2020)

InRange: Comparison of the Second-Generation Basal Insulin Analogues Glargine 300 U/mL and Degludec 100 U/mL in Persons with Type 1 Diabetes Using Continuous Glucose Monitoring—Study Design
por: Battelino, Tadej, et al.
Publicado: (2020)

Comparative clinical outcomes of insulin degludec and insulin glargine 300 U/mL after switching from other basal insulins in real‐world patients with type 1 and type 2 diabetes
por: Oya, Junko, et al.
Publicado: (2021)

Commentary to “Differential Effect of Hypoalbuminemia on Hypoglycemia on Type 2 Diabetes Patients Treated with Insulin Glargine 300 U/ml and Insulin Degludec” by Kawaguchi et al. Diabetes Therapy 2019
por: Pieber, Thomas R., et al.
Publicado: (2020)

Low within- and between-day variability in exposure to new insulin glargine 300 U/ml
por: Becker, R H A, et al.
Publicado: (2015)

Insulin glargine 300 U/mL in the management of diabetes: clinical utility and patient perspectives
por: de Galan, Bastiaan E
Publicado: (2016)

Insulin Glargine 300 U/mL Therapy in Children and Adolescents with Type 1 Diabetes
por: Maffeis, Claudio, et al.
Publicado: (2022)

Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus
por: Lau, Ip Tim, et al.
Publicado: (2017)

Comparisons of efficacy and safety in insulin glargine and lixisenatide plus glulisine combination therapy with multiple daily injection therapy in Japanese patients with type 2 diabetes
por: Kawaguchi, Yuji, et al.
Publicado: (2021)

Insulin doses requirements in patients with type 1 diabetes using glargine U300 or degludec in routine clinical practice
por: Carral San Laureano, Florentino, et al.
Publicado: (2021)

Efficacy and safety of insulin glargine 300 U/mL versus insulin glargine 100 U/mL in Asia Pacific insulin‐naïve people with type 2 diabetes: The EDITION AP randomized controlled trial
por: Ji, Linong, et al.
Publicado: (2019)

Continuous glucose monitoring‐based time‐in‐range using insulin glargine 300 units/ml versus insulin degludec 100 units/ml in type 1 diabetes: The head‐to‐head randomized controlled InRange trial
por: Battelino, Tadej, et al.
Publicado: (2022)

Differential glycaemic control with basal insulin glargine 300 U/mL versus degludec 100 U/mL according to kidney function in type 2 diabetes: A subanalysis from the BRIGHT trial
por: Haluzík, Martin, et al.
Publicado: (2020)

Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial
por: Philis-Tsimikas, Athena, et al.
Publicado: (2020)

Ease of Use of the Insulin Glargine 300 U/mL Pen Injector in Insulin-Naïve People With Type 2 Diabetes
por: Pohlmeier, Harald, et al.
Publicado: (2017)

New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3)
por: Bolli, G B, et al.
Publicado: (2015)

Efficacy and Safety of Insulin Glargine 300 U/mL versus 100 U/mL in Diabetes Mellitus: A Comprehensive Review of the Literature
por: Vargas-Uricoechea, Hernando
Publicado: (2018)

Efficacy and Safety of Switching Patients Inadequately Controlled on Basal Insulin to Insulin Glargine 300 U/mL: The TRANSITION 2 Study
por: Gourdy, Pierre, et al.
Publicado: (2019)

Controlling glycemic variability in people living with type 1 diabetes receiving insulin glargine 300 U/mL (Gla-300)
por: Mader, Julia K, et al.
Publicado: (2022)

Cost-Effectiveness of Insulin Degludec vs. Insulin Glargine U100 in Type 1 and Type 2 Diabetes Mellitus in a UK Setting
por: Evans, Marc, et al.
Publicado: (2018)

Comparative effectiveness and safety of glargine 300 U/mL versus degludec 100 U/mL in insulin-naïve patients with type 2 diabetes. A multicenter retrospective real-world study (RESTORE-2 NAIVE STUDY)
por: Fadini, Gian Paolo, et al.
Publicado: (2022)

Efficacy and Safety of Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in High-Risk and Low-Risk Patients with Type 2 Diabetes Stratified Using Common Clinical Performance Measures
por: Lingvay, Ildiko, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_r9tf5d0fhj116bdjq9d7jde7hm